BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan 29th Annual Healthcare...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed to exchange $87.0 million in aggregate...

Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2010 Q3 2009 Comparison Total BioMarin Revenue $97.8 21.0% increase Total Net Product Revenue $96.6 23.2% increase...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young...

BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences...

BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...

BioMarin Pharmaceutical Inc. announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society...

BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor...

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the...

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on...

Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2010 Q2 2009 Comparison Total BioMarin Revenue $92.0 11.1% increase Total Net Product Revenue $90.6 11.2% increase...

BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data...

BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 2, at 5:00 p.m. ET to...

BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Wells Fargo Healthcare Conference in Boston on Thursday,...

BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Goldman Sachs 31st Annual Healthcare Conference in Los...

BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Executive Vice President and Chief Business Officer of BioMarin, will present a company update at the William Blair 30th Annual...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Wednesday,...

BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the JMP Securities Research Conference in...

Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2010 Q1 2009 Comparison Total BioMarin Revenue $85.0 14.8% increase Total Net Product Revenue $84.1 16.9% increase...

BioMarin Pharmaceutical Inc. today announced positive results for the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage...

BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Executive Vice President and Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank 35th Annual...

BioMarin Pharmaceutical Inc. announced today that Firdapse(TM) (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 5:00 p.m. ET to...

BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...

BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Cowen and Company 30th Annual Health Care Conference in...

BioMarin Pharmaceutical Inc. announced today that it has partnered with industry and patient advocacy organizations in an international effort to raise awareness of rare diseases which affect...

Financial Highlights ($ in millions, except per share data) Item FY 2009 FY 2008 Comparison Total BioMarin Revenue $324.7 9.5% increase Total Net Product Revenue $315.7 25.4% increase Naglazyme...

BioMarin Pharmaceutical Inc. today announced 2010 financial guidance. The reconciliation of the non-GAAP measures to the estimated GAAP net income is detailed in the table provided in the press...

BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage...

BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 12th Annual BIO CEO and Investor Conference in...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February 23, at 5:00 p.m. ET to...

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in the Phase 1 clinical study of BMN 195, a small molecule utrophin upregulator, for the treatment of...

BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 28th Annual J.P. Morgan Healthcare Conference in...

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ OMX 23rd Investor Program in London on...

BioMarin Pharmaceutical Inc. announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing...

BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on...

Financial Highlights ($ in millions, except per share data) Item Q3 2009 Q3 2008 Comparison Total BioMarin Revenue $80.8 11% increase Total Net Product Revenue $78.4 16% increase Naglazyme Net...

BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Oppenheimer Healthcare Conference in New York City on...

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine...

BioMarin Pharmaceutical Inc. announced today that its Chief Executive Officer Jean-Jacques Bienaime will receive the Most Admired CEO Award from the San Francisco Business Times at a gala event to...

BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has allowed claims covering the approved administration of Kuvan® (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 28, at 5:00 p.m. ET to...

BioMarin Pharmaceutical Inc. announced today that the first patient has initiated treatment in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Healthcare Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Hank Fuchs, M.D., Senior Vice President and Chief Medical Officer of BioMarin, will present a company update at the Baird Healthcare Conference in...

BioMarin Pharmaceutical Inc. today announced that Jeffrey H. Cooper, Senior Vice President and Chief Financial Officer of BioMarin, will present a company update at the Thomas Weisel Partners...

BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan (sapropterin dihydrochloride) and Naglazyme (galsulfase) will be presented at the 11th Annual Meeting of the...

Financial Highlights ($ in millions, except per share data) Item Q2 2009 Q2 2008 Comparison Total BioMarin Revenue $82.8 29% increase Total Net Product Revenue $81.5 35% increase Naglazyme Net...

BioMarin Pharmaceutical Inc. announced today that the United States Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan...

BioMarin Pharmaceutical Inc. announced today that patient enrollment has been completed for the Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00...

BioMarin Pharmaceutical Inc. announced today that the temporary interruption of bulk production at Genzyme's Allston Landing manufacturing facility is not expected to have any impact on Aldurazyme...

BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin, will present a company update at the Jefferies Healthcare Conference...

BioMarin Pharmaceutical Inc. announced today that it has received notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for patients with phenylketonuria...

BioMarin Pharmaceutical Inc. today announced results from the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Goldman Sachs 30th Annual Global Healthcare...

BioMarin Pharmaceutical Inc. announced today that it has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD), an organization dedicated to improving the...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Deutsche Bank 34th Annual Health Care Conference...

BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Baird Growth Stock Conference...

Financial Highlights ($ in millions, except per share data) Item Q1 2009 Q1 2008 Comparison Total BioMarin Revenue $74.0 23% increase Total Net Product Revenue $71.9 25% increase Naglazyme Net...

BioMarin Pharmaceutical Inc. announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 5:00 p.m. ET (23:00...

BioMarin Pharmaceutical Inc. announced today that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan(R)...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 4th Annual Citi Biotech Day in New York City on...

BioMarin Pharmaceutical Inc. announced today that its application for clinical trial authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the...

BioMarin Pharmaceutical Inc. today announced that Jeffrey H. Cooper, Senior Vice President and Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 29th...

BioMarin Pharmaceutical Inc. today announced that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the Barclays Capital Global...

BioMarin Pharmaceutical Inc. announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility during an inspection...

BioMarin Pharmaceutical Inc. announced today the appointment of Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer (CMO). Dr. Fuchs will replace longtime BioMarin CMO, Dr. Emil...

BioMarin Pharmaceutical Inc. announced today that it will participate in a coalition of organizations led by the National Organization for Rare Disorders (NORD) to support the observance of Rare...

Financial Highlights ($ in millions, except per share data) Item FY 2008 FY 2007 Comparison Total BioMarin Revenue $296.5 143.9% increase Naglazyme Net Product Revenue $132.7 53.9% increase...

BioMarin Pharmaceutical Inc. announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that...

BioMarin Pharmaceutical Inc. announced today that ANVISA, Brazil's National Health Surveillance Agency, has granted BioMarin marketing approval for Naglazyme(R) (galsulfase) for the treatment of...

BioMarin Pharmaceutical Inc. today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 27th Annual J.P. Morgan Healthcare Conference in...

BioMarin Pharmaceutical Inc. and La Jolla Pharmaceutical Company announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug...

BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan(R) (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with...

BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA...